Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 11-12, 2004, Pages 811-816

  Brandén, Eva ^a,d   Koyi, Hirsh ^a   Gnarpe, Judy ^b   Gnarpe, Håkan ^c   Tornling, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMAX; AZITHROMYCIN; BACTERIUM ANTIBODY; PLACEBO;

ABDOMINAL PAIN; ADULT; ANTIBODY TITER; ARTICLE; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; ERADICATION THERAPY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INCREASED APPETITE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SYMPTOM; TREATMENT OUTCOME; XEROSTOMIA;

ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; AZITHROMYCIN; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 11344289183     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540512331336622     Document Type: Article

References (38)

1. Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6: 19-22.
2. Mogulkoc N, Karakurt S, Isalska B, Bayindir U, Celikel T, Korten CV, Colpan N. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160: 349-53.
3. Von Hertzen L, Isoaho R, Leinonen M, Koskinen R, Laippala P, Toyryla M, et al. Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int J Epidemiol 1996; 25: 658-64.
4. Von Hertzen L, Alakarppa H, Koskinen R, Liippo K, Surcel HM, Leinonen M, Saikku P. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 1997; 118: 155-64.
5. Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. Jama 1991; 266: 225-30.
6. Hahn DL. Chlamydia pneumoniae, asthma, and COPD: what is the evidence? Ann Allergy Asthma Immunol 1999; 83: 271-92.
7. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-8.
8. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9.
9. Koyi H, Branden E, Gnarpe J, Gnarpe H, Steen B. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. Apmis 2001; 109: 572-80.
10. Jackson LA, Wang SP, Nazar-Stewart V, Grayston JT, Vaughan TL. Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 1263-6.
11. Grayston JT, Campbell LA, Kuo CC, Mordhorst CIL Saikku P, Thom DH, Wang SP. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-25.
12. Byrne G. Host cell relationship. In: Barron A, ed. Microbiology of Chlamydia. Florida: Boca Raton; 1988. p. 135-50.
13. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48: 691-703.
14. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 105: 1298-303.
15. Bin XX, Wolf K, Schaffner T, Malinverni R. Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice. Antimicrob Agents Chemother 2000; 44: 1761-4.
16. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 1998; 42: 194-6.
17. Grayston JT. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 2003; 107: 1228-30.
18. Gnarpe J, Sparr A, Naas J, Lundback A. Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration. Apmis 2000; 108: 357-62.
19. Gnarpe J, Naas J, Lundback A. Comparison of a new commercial EIA kit and the micrommumofluorescence technique for the determination of IgG and IgA antibodies to Chlamydia pneumoniae. Apmis 2000; 108: 819-24.
20. ATS. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136: 225-44.
21. Berglund E, Birath G, Bjure J, Grimby G, Kjellmer I, Sandqvist L, Soderholm B. Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 y of age. Acta Med Scand 1963; 173: 185-92.
22. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
23. Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, Allegra L. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002; 57: 672-6.
24. Falck G, Gnarpe J, Hansson LO, Svardsudd K, Gnarpe H. Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome. Chest 2002; 122: 1587-93.
25. Strachan DP, Carrington D, Mendall M, Butland BK, Yarnell JW, Elwood P. Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease. Am J Respir Crit Care Med 2000; 161: 493-7.
26. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492-503.
27. Tomasi TB, Grey HM. Structure and function of immunoglobulin A. Prog Allergy 1972; 16: 81-213.
28. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998; 19: 570-7.
29. Gnarpe H, Gnarpe J, Lundback A. Evidence of 2 waves of Chlamydia pneumoniae infection in Gavle, Sweden, 1990-96. Scand J Infect Dis 1999; 31: 83-6.
30. Gnarpe J, Eriksson K, Gnarpe H. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996; 40: 1843-5.
31. Kutlin A, Roblin PM, Hammerschlag MR. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. Antimicrob Agents Chemother 2002; 46: 409-12.
32. Kutlin A, Roblin PM, Hammerschlag MR. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 1999; 43: 2268-72.
33. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-6.
34. Olsen KM, San Pedro G, Gann LP, Gubbins PO, Halinski DM, Campbell GD Jr. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40: 2582-5.
35. Pankuch GA, Jueneman SA, Davies TA, Jacobs MR, Appelbaum PC. In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2914-8.
36. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-7.
37. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. Jama 2003; 290: 1459-66.
38. Anderson JL, Muhlestein JB. The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). J Infect Dis 2000; 181(Suppl 3): S569-71.